BETA

IPO registrations (S-1, F-1) · Registrants

Anthera Pharmaceuticals Inc

SEC CIK
1316175 · filings on EDGAR ↗
Registration
Form S-1, first filed 2009-09-15, last 2010-11-17; 3 initial registrations, 6 amendments
Outcome
Final prospectus filed 2010-03-02; declared effective 2010-02-23
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
25801 INDUSTRIAL BOULEVARD, SUITE B, Hayward, CA 94545
EIN
20-1852016
EDGAR entity type
operating
Insiders and CEO pay
Anthera Pharmaceuticals Inc on the corporate pages

Offering terms

Proposed price range
$13.00–$15.00 per share (S-1/A filed 2010-02-23)
Final price
$7.00 per share, below the range (424B1 filed 2010-03-02, an initial public offering)
Shares sold
6,000,000
Gross proceeds
$42,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol ANTH
Lead underwriters
Cowen
Syndicate
Curhan Ford; Table of; Deutsche Bank; Piper Sandler

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 19

FiledFormWhat it isName as filedEDGAR
2009-09-15S-1S-1 (registration)Anthera Pharmaceuticals Inc0000950123-09-043360 ↗
2009-10-19S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-09-051089 ↗
2009-11-16S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-09-063187 ↗
2010-01-29S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-10-006282 ↗
2010-02-03S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-10-007929 ↗
2010-02-23S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-10-015539 ↗
2010-02-23EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-10-000575 ↗
2010-02-26EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-10-000616 ↗
2010-03-02424B1424B1 (final prospectus)Anthera Pharmaceuticals Inc0000950123-10-020101 ↗
2010-10-22S-1S-1 (registration)Anthera Pharmaceuticals Inc0000950123-10-095295 ↗
2010-11-03EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-10-003138 ↗
2010-11-08S-1S-1 (registration)Anthera Pharmaceuticals Inc0000950123-10-101961 ↗
2010-11-17S-1/AS-1/A (amendment)Anthera Pharmaceuticals Inc0000950123-10-106390 ↗
2010-11-18EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-10-003306 ↗
2011-03-11EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-11-000660 ↗
2011-03-11EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-11-000661 ↗
2011-03-11EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-11-000664 ↗
2011-07-05EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-11-002046 ↗
2012-01-24EFFECTEFFECT (declared effective)Anthera Pharmaceuticals Inc9999999995-12-000291 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2010-02-23S-1/Aregistration statement$13.00–$15.004,607,142-Nasdaq ANTH5primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 5document ↗
2010-03-02424B1final prospectus$7.006,000,000$42,000,000Nasdaq ANTH5primary document; price sentence, shares headline, proceeds table, cover names 5document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Bianchi AnnetteDirector32010–2011
Fritsch UrsulaOfficerVP, Glob. Reg. and Compliance; VP, Glob. Reg. & Compliance32010
HEALY JAMESDirector; Director,TenPercentOwner112010–2013
HENNEY CHRISTOPHER SDirector142010–2018
Hislop ColinOfficerChief Medical Officer; Sr. VP, Cardiovasc. Prod.222010–2016
Lau StephenOfficerVP, Corp. & Business Dev.22010
Leheny A. RachelDirector42010
LOWE CHRISTOPHER P.OfficerC.F.O. and C.B.O.; CFO and Chief Business Officer; CFO & VP of Administration; Chief Financial Officer & CBO; VP of Administration and CBO212010–2013
ODINK DEBRADirector,Officer; OfficerChief Technology Officer; VP, Pharmaceutical R&D232010–2015
PENNINGTON JAMES EOfficerChief Medical Officer & Ex. VP12010
SALZMAN ALAN ETenPercentOwner102010–2011
Santel Donald JDirector32010–2011
Sofinnova Management VI, L.L.C.TenPercentOwner62010–2012
SOFINNOVA VENTURE PARTNERS VI L PTenPercentOwner62010–2012
SPIEGELMAN DANIEL KDirector72010–2014
Thompson David E.Director152010–2018
Trias JoaquimOfficerSr. VP, Preclinical Developmen; SR VP, Preclinical Development42010
TRUEX PAUL FDirector; Director,Officer; OfficerChief Executive Officer; Executive Chaiman; Executive Chairman; President and C.E.O.; President and CEO; President and Chief Executive412010–2018
VANTAGEPOINT VENTURE ASSOCIATES IV LLCTenPercentOwner102010–2011
VANTAGEPOINT VENTURE PARTNERS IV LPTenPercentOwner102010–2011
VANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS FUND LPTenPercentOwner102010–2011
VANTAGEPOINT VENTURE PARTNERS IV Q LPTenPercentOwner102010–2011
KILFOIL GEORGINAOfficerSVP, Prod. Dev. & Project Mngm; SVP,Product Dev.& Project Mgmt92010–2013
ISALY SAMUEL DDirector; Director,TenPercentOwner; TenPercentOwner132010–2013
ORBIMED ADVISORS LLCDirector; Director,TenPercentOwner; TenPercentOwner132010–2013
OrbiMed Capital GP IV LLCDirector; Director,TenPercentOwner; TenPercentOwner132010–2013
Thompson Peter A.Director32011–2012
Azan AlainTenPercentOwner42011–2012
Buatois EricTenPercentOwner42011–2012
POWELL MICHAELTenPercentOwner42011–2012
Sofinnova Venture Affiliates VI LPTenPercentOwner42011–2012
Sofinnova Venture Partners VI GmbH & Co. KGTenPercentOwner42011–2012
DZIURZYNSKI BOGDANDirector52012–2013
ZWEIFACH SANFORD SDirector52013–2015
LIU MAYOfficerChief Accounting Officer; Principal Accounting Officer; SVP, Finance & Administration122013–2018
ENGLE STEVEN BDirector52014–2016person page Fuzzy
Sager PhilipDirector62014–2018
Mueller BrianDirector72014–2018
Zenyaku Kogyo Co., Ltd.TenPercentOwner12015
Dickinson KlaraOfficerChief Regulatory Officer; SVP & Chief Regulatory Office; SVP & Chief Regulatory Officer62015–2017
THOMPSON JOHN CRAIGDirector,Officer; OfficerChief Executive Officer; President & CEO; President & COO112016–2018
Olson Charles VOfficerChief Technology Officer; CHIEF TECHNOLOGY OFFICER52016–2017
Pennington JamesOfficerInterim Chief Medical Officer12016
Furse BrentDirector22016–2018
SHANAHAN WILLIAM R JRDirector,Officer; OfficerChief Medical Officer32016–2018
McManigle Mark DrewDirector,OfficerChief Liquidating Officer12018

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2017-11-09Anthera Pharmaceuticals IncBiotechnology$15,000,000$15,000,000212

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
ContractorANTHERA PHARMACEUTICALSCANonprofit contractors (Form 990)name and state
Plan sponsorANTHERA PHARMACEUTICALS, INC.CAForm 5500 (employee benefit plans)name and state
Form D issuerAnthera Pharmaceuticals IncCAForm D private offeringsCIK (EXACT)
Lobbying clientANTHERA PHARMACEUTICALS, INC.CAFederal lobbying (LDA)name and state
Patent assigneeAnthera Pharmaceuticals, Inc.CAPatents (USPTO)name and state
SEC filerAnthera Pharmaceuticals IncSEC filers (EDGAR)CIK (EXACT)
Trademark ownerAnthera Pharmaceuticals, Inc.CATrademarks (USPTO)name and state
Form 5500 plan sponsorANTHERA PHARMACEUTICALS, INC.EIN (EXACT)
Person pageSteven B EnglePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, CA first:

More with this interest.

In other datasets, the same topic (Health) in CA:

Interests: Pharmaceutical Preparations · Health